18 citations
,
February 2021 in “Archives of Dermatological Research” This study found that Physcion from Polygonum multiflorum may be an effective natural 5α-reductase inhibitor for treating androgenic alopecia by enhancing hair growth and improving follicle morphology in laboratory settings.
30 citations
,
October 2020 in “Nature Communications” This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
43 citations
,
November 2019 in “American Journal of Clinical Dermatology” This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.
38 citations
,
February 2019 in “Clinical Interventions in Aging” This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.
11 citations
,
December 2018 in “Assay and Drug Development Technologies” This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.
12 citations
,
March 2017 in “Medicinal Chemistry Research” This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.
17 citations
,
December 2015 in “BMC Complementary and Alternative Medicine” This study found that Avicennia marina extract significantly inhibited 5α-reductase type 1 activity in human hair dermal papilla cells, suggesting its potential use for treating androgenic alopecia.
37 citations
,
January 2015 in “Evidence-based Complementary and Alternative Medicine” This study found that Bokusoku extract and its compound pentagalloyl glucose inhibited testosterone metabolism and sebum synthesis, suggesting potential therapeutic use for androgen-related acne.
18 citations
,
November 2014 in “Journal of Agricultural and Food Chemistry” This study found that ethanol-extracted propolis stimulated hair growth in mice by promoting the proliferation of hair keratinocytes.
59 citations
,
May 2014 in “Expert Opinion on Therapeutic Targets” This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.
19 citations
,
May 2014 in “Molecules” This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.
151 citations
,
May 2014 in “American Journal of Clinical Dermatology” This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.
186 citations
,
December 2011 in “Molecules” This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.
218 citations
,
December 2011 in “Advances in Urology” This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.
34 citations
,
August 2011 in “Journal of Natural Medicines” This study found that Puerariae Flos extract inhibited testosterone 5α-reductase and promoted hair growth in mouse models, suggesting its potential use for treating androgenic alopecia.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
44 citations
,
January 2007 in “Biological & pharmaceutical bulletin” This study found that Piper nigrum leaf extract showed in vivo anti-androgenic activity and potent 5α-reductase inhibitory effects, with piperine and (−)-cubebin identified as active components.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.
45 citations
,
February 2005 in “Steroids” This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.
22 citations
,
February 2002 in “Planta Medica” In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.
416 citations
,
September 1997 in “Journal of Investigative Dermatology” People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.
136 citations
,
March 1996 in “Journal of the American Chemical Society” This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.
64 citations
,
June 1995 in “Steroids” This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.
101 citations
,
April 1994 in “Baillière's clinical endocrinology and metabolism” This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.